000950 重药控股
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入62,211,4024.22%80,561,53278,397,35467,829,01062,520,755
减:营业总成本61,116,4403.48%79,839,41277,352,03866,608,40261,148,245
    其中:营业成本57,722,5654.47%74,572,95872,130,85162,008,78056,782,329
               财务费用557,907-31.45%1,084,2811,302,0281,094,2351,087,649
               资产减值损失(19,865)102.94%(89,975)(27,756)(39,943)(12,883)
公允价值变动收益(861)-112.22%6,91916,1622,318126,883
投资收益139,992-42.13%402,412301,548293,349302,690
    其中:对联营企业和合营企业的投资收益224,461-7.89%396,688291,454286,195279,408
营业利润665,17121.37%562,641964,8831,435,0111,560,927
利润总额657,43620.17%557,508966,3291,472,4901,580,286
减:所得税费用125,058-10.82%155,717236,042309,496289,613
净利润532,37830.86%401,791730,2881,162,9951,290,673
减:非控股权益148,36729.45%118,798105,654210,719285,229
股东净利润384,01031.41%282,994624,633952,2761,005,444

市场价值指针
每股收益 (元) *0.22029.41%0.1600.3600.5500.580
每股派息 (元) *0.0300.00%0.0600.0500.0600.105
每股净资产 (元) *6.6871.05%6.5546.5076.1105.633
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容